![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pharmacology and the Fiske Drug Discovery Laboratory (M.B., T.N., A.V., J.Y., A.G., J.S.L.), Department of Chemistry and the Center for Chemical Methodologies and Library Development (C.R.J.S., P.W.), and the Center for Computational Biology and Bioinformatics (D.T., I.B.), University of Pittsburgh, Pittsburgh, Pennsylvania
Cdc25A and Cdc25B dual-specificity phosphatases are key regulators of cell cycle transition and proliferation. They have oncogenic properties and are overexpressed in many human tumors. Because selective Cdc25 phosphatase inhibitors would be valuable biological tools and possible therapeutic agents, we have assayed a small molecule library for in vitro inhibition of Cdc25. We now report the identification of two new structurally distinct classes of Cdc25 inhibitors with cellular activity. The cyclopentaquinoline 3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,8-dicarboxylic acid (5661118) and the naphthofurandione 3-benzoyl-naphtho[1,2-b]furan-4,5-dione (5169131) had in vitro IC50 values of 2.5 to 11 µM against recombinant Cdc25 and were less potent inhibitors of other phosphatases. Unlike 5661118, 5169131 caused reversible inhibition of Cdc25B and displayed competitive inhibitor kinetics. No growth inhibitory activity was seen with 5661118, whereas 10 to 30 µM 5169131 caused G1/S and G2/M arrest. We also found that 5169131 inhibited human PC-3 prostate and MDA-MB-435 breast cancer cell proliferation. Concentration-dependent Tyr15 hyperphosphorylation was seen on cyclin-dependent kinase with a 1-h 5169131 treatment, consistent with Cdc25 inhibition. Cells resistant to DNA toposiomerase II inhibitors were as sensitive to 5169131 as parental cells, indicating that this quinone compound does not inhibit topoisomerase II in vivo. Molecular modeling was used to predict a potential interaction site between the inhibitor and Cdc25B and to provide insights as to the molecular origins of the experimental observations. Based on its kinetic profile and cellular activity, we suggest that 5169131 could be an excellent tool for further studies on the cellular roles of Cdc25.
Address correspondence to: John S. Lazo, Department of Pharmacology, University of Pittsburgh, E1340 Biomedical Science Tower, Pittsburgh, PA 15261-0001. E-mail: lazo{at}pitt.edu
This article has been cited by other articles:
|
|
 |
|
  M. Cazales, R. Boutros, M.-C. Brezak, S. Chaumeron, G. Prevost, and B. Ducommun Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly Mol. Cancer Ther., January 1, 2007; 6(1): 318 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brisson, C. Foster, P. Wipf, B. Joo, R. J. Tomko Jr., T. Nguyen, and J. S. Lazo Independent Mechanistic Inhibition of Cdc25 Phosphatases by a Natural Product Caulibugulone Mol. Pharmacol., January 1, 2007; 71(1): 184 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brisson, T. Nguyen, P. Wipf, B. Joo, B. W. Day, J. S. Skoko, E. M. Schreiber, C. Foster, P. Bansal, and J. S. Lazo Redox Regulation of Cdc25B by Cell-Active Quinolinediones Mol. Pharmacol., December 1, 2005; 68(6): 1810 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Brezak, M. Quaranta, M.-O. Contour-Galcera, O. Lavergne, O. Mondesert, P. Auvray, P. G. Kasprzyk, G. P. Prevost, and B. Ducommun Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases Mol. Cancer Ther., September 1, 2005; 4(9): 1378 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rudolph Targeting the Neighbor's Pool Mol. Pharmacol., October 1, 2004; 66(4): 780 - 782. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
